Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 11/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | CDK4 | P11802 | 1/20 | 0.35 |
| ▸ | CCND1 | P24385 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5771644 | 1.00 | ATR (0.42) | ATRKDM5AMAP4K4HRH3HCRTR1 | |
| SCHEMBL5773750 | 0.92 | ATR (0.41) | ATRMAP4K4HRH3JAK2MCHR1 | |
| SCHEMBL5774263 | 0.91 | ATR (0.40) | ATRMAP4K4HCRTR1HCRTR2MCHR1 | |
| SCHEMBL5772822 | 0.91 | KDM5A (0.39) | ATRKDM5AMAP4K4HRH3JAK2 | |
| SCHEMBL5768174 | 0.91 | KDM5A (0.39) | ATRKDM5AMAP4K4HRH3JAK2 | |
| SCHEMBL5769639 | 0.90 | ATR (0.43) | ATRMAP4K4HCRTR1HCRTR2JAK2 | |
| SCHEMBL5811219 | 0.90 | ATR (0.40) | ATRMAP4K4HRH3HCRTR1HCRTR2 | |
| SCHEMBL5769155 | 0.89 | ATR (0.39) | ATRKDM5AMAP4K4HRH3HCRTR1 | |
| SCHEMBL5772696 | 0.89 | ATR (0.39) | ATRKDM5AMAP4K4HRH3HCRTR1 | |
| SCHEMBL5873060 | 0.86 | DYRK1A (0.40) | ATRKDM5AHCRTR1HCRTR2CDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | claimed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | claimed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | claimed |
| EP-1664040-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| WO-2005026162-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | ATR 919/4885KDM5A 2543/4885MAP4K4 2320/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | ATR 919/4885KDM5A 2543/4885MAP4K4 2320/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.